Related Experiment Videos
Impact of new immunosuppressive agents on late graft outcome
1Department of Nephrology, University Hospital Gasthuisberg, Leuven, Belgium.
Abstract:
Several new immunosuppressive agents have recently been launched for clinical use after kidney transplantation. FK506 or tacrolimus (Prograf) has been tested as an alternative for cyclosporine A (CsA). Both tacrolimus and CsA interfere with the early stage of lymphocyte proliferation by blocking interleukin-2 synthesis. Mycophenolate mofetil (MMF) (Cell-Cept) blocks the de novo synthesis of guanine nucleotides, the pathway essential for purine synthesis in dividing T- and B-lymphocytes, and has been used in conjunction with CsA and corticosteroids. In several prospective randomized trials a significant reduction in the incidence of acute rejection has been shown. As early acute rejection and especially recurrent acute rejection, is one of the most important risk factors for chronic rejection and late graft loss, there is a growing interest in the potential beneficial effect of these drugs on the late graft survival. In the European MMF trial, a further reduction of the late graft loss after one year is seen for patients treated with 2 g MMF. A retrospective comparison of international registry data has also shown a significant increase in the graft half-life of patients receiving tacrolimus compared with CsA treated patients. Taking into account the still limited follow-up of the available trials and the fact they were not primarily designed with adequate statistical benefits of these new drugs on the late graft outcome must be made with caution.
Insights
New immunosuppressants like tacrolimus and mycophenolate mofetil show promise in reducing kidney transplant rejection. While early results are encouraging for graft survival, long-term benefits require further investigation.
Area of Science:
- Nephrology
- Immunology
- Transplantation Medicine
Background:
- Kidney transplantation relies on immunosuppressive agents to prevent graft rejection.
- Cyclosporine A (CsA) has been a standard, but newer agents offer alternative mechanisms of action.
Purpose of the Study:
- To evaluate the efficacy of new immunosuppressive agents, specifically tacrolimus and mycophenolate mofetil (MMF), in kidney transplant recipients.
- To assess the impact of these agents on acute and chronic rejection, and overall graft survival.
Main Methods:
- Review of prospective randomized trials and retrospective registry data comparing tacrolimus and MMF with CsA.
- Analysis of outcomes including acute rejection incidence, chronic rejection, and graft survival rates.
Main Results:
- Both tacrolimus and MMF demonstrated a reduction in acute rejection episodes compared to CsA.
- The European MMF trial indicated a reduction in late graft loss at one year with MMF.
- Retrospective data suggested improved graft half-life with tacrolimus compared to CsA.
Conclusions:
- Newer immunosuppressants like tacrolimus and MMF show potential benefits in managing kidney transplant rejection.
- While promising for acute rejection and early graft survival, cautious interpretation of long-term graft survival benefits is warranted due to limited follow-up data.